111 Capital Sells 421 Shares of DexCom, Inc. $DXCM

111 Capital lessened its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 2.6% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 15,964 shares of the medical device company’s stock after selling 421 shares during the quarter. 111 Capital’s holdings in DexCom were worth $1,393,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in DXCM. Vanguard Group Inc. boosted its holdings in DexCom by 2.0% in the 1st quarter. Vanguard Group Inc. now owns 47,455,899 shares of the medical device company’s stock worth $3,240,763,000 after buying an additional 925,882 shares during the period. Jennison Associates LLC boosted its holdings in shares of DexCom by 37.7% in the first quarter. Jennison Associates LLC now owns 10,523,246 shares of the medical device company’s stock worth $718,632,000 after acquiring an additional 2,879,489 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of DexCom by 22.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 10,123,525 shares of the medical device company’s stock worth $691,336,000 after acquiring an additional 1,868,241 shares during the period. Nuveen LLC bought a new position in shares of DexCom in the first quarter worth $554,893,000. Finally, Raymond James Financial Inc. boosted its stake in DexCom by 21.8% in the 1st quarter. Raymond James Financial Inc. now owns 3,355,057 shares of the medical device company’s stock worth $229,117,000 after purchasing an additional 601,088 shares during the period. Institutional investors own 97.75% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have commented on DXCM. Morgan Stanley raised their target price on DexCom from $82.00 to $89.00 and gave the stock an “equal weight” rating in a research note on Tuesday, July 15th. Oppenheimer lowered shares of DexCom from an “outperform” rating to a “market perform” rating in a research report on Monday, September 8th. The Goldman Sachs Group cut their price target on shares of DexCom from $104.00 to $89.00 and set a “buy” rating for the company in a report on Wednesday. Raymond James Financial raised their price target on shares of DexCom from $99.00 to $102.00 and gave the company a “strong-buy” rating in a report on Thursday, July 31st. Finally, Mizuho raised their price target on shares of DexCom from $95.00 to $100.00 and gave the company an “outperform” rating in a report on Wednesday, July 16th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $98.32.

DexCom Stock Performance

NASDAQ DXCM opened at $67.05 on Friday. DexCom, Inc. has a 52-week low of $57.52 and a 52-week high of $93.25. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.35 and a current ratio of 1.52. The company has a market capitalization of $26.29 billion, a P/E ratio of 46.56, a P/E/G ratio of 1.39 and a beta of 1.47. The company has a fifty day moving average of $76.31 and a 200-day moving average of $77.88.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Wednesday, July 30th. The medical device company reported $0.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.45 by $0.03. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The company had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. During the same period in the previous year, the firm posted $0.43 EPS. The firm’s revenue was up 15.2% compared to the same quarter last year. DexCom has set its FY 2025 guidance at EPS. As a group, equities research analysts predict that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Insider Transactions at DexCom

In related news, EVP Sadie Stern sold 1,466 shares of the business’s stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $80.00, for a total value of $117,280.00. Following the completion of the sale, the executive vice president owned 105,223 shares in the company, valued at $8,417,840. The trade was a 1.37% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Mark G. Foletta sold 2,750 shares of the business’s stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $81.06, for a total value of $222,915.00. Following the completion of the sale, the director owned 51,121 shares of the company’s stock, valued at $4,143,868.26. The trade was a 5.10% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 6,849 shares of company stock worth $564,733. 0.32% of the stock is currently owned by company insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.